Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Operating Expenses (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Operating Expenses for 3 consecutive years, with $3.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Operating Expenses fell 7.27% year-over-year to $3.6 million, compared with a TTM value of $12.8 million through Dec 2024, down 26.53%, and an annual FY2024 reading of $12.8 million, down 26.53% over the prior year.
  • Operating Expenses was $3.6 million for Q4 2024 at Oramed Pharmaceuticals, up from $3.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $11.7 million in Q2 2022 and bottomed at $3.0 million in Q1 2024.
  • Average Operating Expenses over 3 years is $6.0 million, with a median of $4.1 million recorded in 2023.
  • The sharpest move saw Operating Expenses tumbled 63.51% in 2023, then dropped 7.27% in 2024.
  • Year by year, Operating Expenses stood at $10.0 million in 2022, then plummeted by 61.24% to $3.9 million in 2023, then fell by 7.27% to $3.6 million in 2024.
  • Business Quant data shows Operating Expenses for ORMP at $3.6 million in Q4 2024, $3.1 million in Q3 2024, and $3.1 million in Q2 2024.